Strategy for Incorporating Molecular and Cytogenetic Markers Into Acute Myeloid Leukemia Therapy

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2008.0075
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

New Molecular Markers in Acute Myeloid Leukemia

2011English

Therapy of Acute Myeloid Leukemia

2012English

How Close Are We to Incorporating Measurable Residual Disease Into Clinical Practice for Acute Myeloid Leukemia?

Haematologica
Hematology
2019English

Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Seminars in Oncology
OncologyHematology
2013English

Molecular Emergence of Acute Myeloid Leukemia During Treatment for Acute Lymphoblastic Leukemia

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Molecular Genetic Studies on Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia - With Focus on Prognostic Markers

2014English

“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Cytogenetic Heterogeneity Negatively Impacts Outcomes in Patients With Acute Myeloid Leukemia

Haematologica
Hematology
2014English

Acute Myeloid Leukemia Therapy and the Chosen People

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy